Premium
Immunogenicity of Avian H5N1 Influenza Virus Recombinant Vaccines in Cats
Author(s) -
Uhl Elizabeth W,
Tompkins S. Mark,
Harvey Stephen B,
Gabbard Jon,
Michel Frank,
Perozo Yaneth,
Hogan Robert J
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.422.7
Subject(s) - virology , influenza a virus subtype h5n1 , immunogenicity , cats , inactivated vaccine , recombinant dna , hemagglutination assay , biology , titer , antibody titer , virus , influenza a virus , hemagglutinin (influenza) , antigen , antibody , microbiology and biotechnology , live attenuated influenza vaccine , influenza vaccine , medicine , immunology , gene , biochemistry
Domesticated cats can be infected with highly pathogenic avian influenza H5N1 virus and potentially can be vector or reservoir hosts in an influenza pandemic. We examined the immunogenicity of the hemagglutinin (HA) of H5N1strain VN/1203/04 in cats. ELISAs showed that a single dose of recombinant H5 HA protein can induce a robust antibody response against both whole inactivated virus and recombinant HA antigen. A marked increase in hemagglutination inhibition (HI) titers was also observed in sera from cats given a single dose of the H5 HA protein. However, cats given the commercial H5N1 vaccine required 2 doses before increased H5 HA‐specific antibody titers were observed. Despite boosting, cats receiving the commercial H5N1 vaccine had HI titers lower than those given one injection of recombinant protein. Cats vaccinated with plasmid DNA encoding HA failed to develop HA‐specific antibody responses. Finally, sera from cats that received the protein vaccine neutralized wild type H5N1 influenza virus (VN/120304). The results of this study indicate that recombinant H5 HA protein‐based vaccines may be more effective that either inactivated influenza virus or DNA vaccines in cats.